Pfizer Defends Nigerian Drug Study


NEW YORK-Pharmaceutical giant Pfizer was left defending itself after an article in The Washington Post found the company reportedly did not follow the necessary procedures before beginning their study of the drug Trovan.

Company officials said they were "proud of the way the study was conducted," although there is now a lawsuit filed in the US District Court of New York on behalf of 30 children who participated in the study. They argue the drug, known as trovafloxacin also, was responsible for the deaths and brain damage of children during a 1996 meningitis outbreak in Nigeria. There were more than 200 children who participated in the study, which took place during an epidemic that killed more than 15,000 Africans.

The lawsuit alleges that Pfizer officials rushed important steps to begin the study, therefore violating international law, federal regulations, and medical ethics.

The article, which ran as a series highlighting medical testing abroad by American pharmaceutical companies, showed that the company did not seek approval from an Nigerian medical ethics committee before starting testing.

Trovan, which was approved by the US Food and Drug Administration (FDA) in 1997, was designed to treat many infections, However, after cases of liver failure, its uses was restricted in 1999.

Information from

Related Videos
Set of white bottles with cleaning liquids on the white background. (Adobe Stock 6338071172112 by zolnierek)
Medical investigators going over data. (AdobeStock 589197902 by Wasan)
CDC logo is seen on a laptop. (Adobe Stock 428450603 by monticellllo)
Association for the Health Care Environment (Logo used with permission)
COVID-19 germs, fungi, bacteria objects. (Adobe Stock 584704860 by chawalit)
Ambassador Deborah Birx, , speaks with Infection Control Today about masks in schools and the newest variant.
mRNA technology  (Adobe Stock 485886181 by kaptn)
Ambassador Deborah Birx, MD
Woman lying in hospital bed (Adobe Stock, unknown)
Related Content